Genentech Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GENENTECH, and when can generic versions of GENENTECH drugs launch?
GENENTECH has nine approved drugs.
There are fifty-nine US patents protecting GENENTECH drugs.
There are nine hundred and eleven patent family members on GENENTECH drugs in fifty-four countries and eighty-seven supplementary protection certificates in nineteen countries.
Summary for Genentech
| International Patents: | 911 |
| US Patents: | 59 |
| Tradenames: | 6 |
| Ingredients: | 6 |
| NDAs: | 9 |
| Patent Litigation for Genentech: | See patent lawsuits for Genentech |
| PTAB Cases with Genentech as patent owner: | See PTAB cases with Genentech as patent owner |
Drugs and US Patents for Genentech
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | AB | RX | Yes | No | 8,013,002 | ⤷ Sign Up | ⤷ Sign Up | |||
| Genentech Inc | XOFLUZA | baloxavir marboxil | TABLET;ORAL | 210854-001 | Oct 24, 2018 | DISCN | Yes | No | 8,987,441 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | AB | RX | Yes | Yes | 7,910,610 | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Genentech
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | 9,561,217 | ⤷ Sign Up |
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | 9,561,217 | ⤷ Sign Up |
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | 9,561,217 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GENENTECH drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 267 mg, 534 mg and 801 mg | ➤ Subscribe | 2018-10-15 |
International Patents for Genentech Drugs
Supplementary Protection Certificates for Genentech Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1789390 | 14C0002 | France | ⤷ Sign Up | PRODUCT NAME: VISMODEGIB AINSI QUE SES SELS ET SOLVATES; NAT. REGISTRATION NO/DATE: EU/1/13/848 20130712; FIRST REGISTRATION: IKS 62497 20130530 |
| 1934174 | C201630028 | Spain | ⤷ Sign Up | PRODUCT NAME: COBIMETINIB; NATIONAL AUTHORISATION NUMBER: EU/1/15/1048; DATE OF AUTHORISATION: 20151120; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1048; DATE OF FIRST AUTHORISATION IN EEA: 20151120 |
| 2176231 | C02176231/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: ENTRECTINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67280 05.11.2020 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
